Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches
Amneal announced that the FDA accepted Amneal’s 505(b)(2) NDA for a newly licensed dihydroergotamine (DHE) prefilled syringe autoinjector
Read moreAmneal announced that the FDA accepted Amneal’s 505(b)(2) NDA for a newly licensed dihydroergotamine (DHE) prefilled syringe autoinjector
Read moreLupin received approval for its Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg, from U.S. FDA
Read moreargenx SE announced it will regain worldwide rights to its anti-CD70 antibody cusatuzumab from Cilag GmbH International
Read moreU.S. FDA Accepts PharmaEssentia’s BLA Resubmission for ropeginterferon alfa-2b-njft for the Treatment of Polycythemia Vera
Read morean additional indication related to central neuropathic pain (CNP) in Japan.
Read morePhase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduction of proteinuria
Read moreLupin announced the launch of its Digital Asthma Educator platform. The platform guides asthma patients on the correct technique of...
Read moreNew data from patritumab deruxtecan demonstrated preliminary evidence of clinically meaningful and durable tumor response in patients
Read moreMr Setu Doshi, Co-founder, Cure World Healthcare. In this Interview, Setu Doshi narrates his journey on setting up a marketing...
Read moreU.S. Food and Drug Administration approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with plasminogen deficiency type 1
Read moreAddress: | Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002. |
Phone: | +91 8511586232, +91 9029066605 |
Email: | author@pharmaregnews.com |
© 2021 - Pharmaregnews.com. Developed by YESWEUS.
© 2021 - Pharmaregnews.com. Developed by YESWEUS.